Nexalin Technology, Inc. · NASDAQ:NXL
Nexalin Technology — Investor Presentation (December 2024)
23 slides from Nexalin Technology's investor presentation, December 2024
Slide 1: Investor Presentation December 2024
Investor Presentation December 2024
Slide 2: Nexalin Forward Looking Statement
Nexalin Forward Looking Statement This presentation material includes forward-looking statements that reflect our current views with respect to future events. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking sta
Slide 3: Company Snapshot
Company Snapshot Our mission at Nexalin Technology is to design and market FDA Class II & III neuro-stimulators for the treatment of: Anxiety – Depression - Insomnia – Dementia – Addiction – TBI / PTSD 3 issued $40MM invested Large patents and 6 $40M since inception $94B addressable pending market 3
Slide 4: Investment Highlights
Investment Highlights Approved treatment indications: • FDA: Anxiety, Insomnia and Depression (Gen-1) • NMPA (China FDA): Depression and Insomnia (Gen-2) Innovative Digital Near-Term Growth Tele-Med Advantage Treatment with Virtual Nexalin’s Gen-3 medical Nexalin will introduce at- home treatment in
Slide 5: Large and Growing Treatment Markets
Large and Growing Treatment Markets Everyone Likely Knows Someone That Needs Help >35% #1 Of reporting adults in Depression is the $210.5 Billion the US have leading cause of Lost earnings per year experienced short sleep disability in the US due to serious mental duration (< 7 hours).2 among ages 1
Slide 6: The Global Mental Health Epidemic
The Global Mental Health Epidemic Insomnia Anxiety Alzheimer’s Addiction Depression 40 million Americans An estimated 31.1% There are over 55 284 million people World Health Organization suffer from chronic of adults experience million people aged 15-64 used (WHO) reports 280 million insomnia. Some
Slide 7: Target Market
Target Market - 6 out of 10 people in need of mental health care will not receive it 1 - Those that do receive care, are usually given medication 58% <50% 75% of patients remission rate of participants experience for the most across studies moderately severe common prefer a non-drug side effects2 me
Slide 8: Industry Approach - Competition
Industry Approach - Competition Current treatment options for common mental health illnesses present more obstacles than solutions for the patient Handheld - tDCS (internet) Pharmaceutical - Drugs & Pills Transcranial Magnetic Stimulation rTMS • Low Efficacy (<2 mA) • Low Efficacy • Low Efficacy • U
Slide 9: Nexalin Approach
Nexalin Approach • High efficacy (4 -15 mA) Features and Benefits • Regulated • Low Risk Profile – 4/15 milliamps (safe) • Safe • Non-Invasive (low ancillary needs) • Nonaddictive • 77.5 htz Frequency (proprietary) • Supported by solid clinical data • Symmetric Square Wave (no voltage) • Disrupts de
Slide 10: Halo Clarity | The Future
Halo Clarity | The Future • Unchanged proprietary technical features • 77.5 Hz @15 milliamps • Unchanged clinical efficacy • FDA Premarket De Novo application • State of the art design and electronics • Home and office Use (removes stigma associated with receiving HALO Clarity Headset mental health
Slide 11: Global Funded Clinical Trial Partnerships
Global Funded Clinical Trial Partnerships Drive acceptance through trials, key opinion leaders and direct sales 11
Slide 12: Clinical Trial Results
Clinical Trial Results Nexalin Technology providers report 75% of patients treated have over 70% improvement and 90% had over 50% improvement of their reported symptoms 1 2 NEXALIN TECHNOLOGY CLINICS ANXIETY DEPRESSION INSOMNIA Diagnosed Average Improvement 77% 74% 84% 1. Insomnia Clinical Trial -Ef
Slide 13: Clinical Trial Results | TBI/PTSD (combat related)
Clinical Trial Results | TBI/PTSD (combat related) MEG Source Imaging Reveals Neuronal Changes in Combat-related Mild Traumatic Brain Injury after Transcranial Electrical Stimulation using Nexalin Objectives: Results: • Veterans in the active treatment group showed significant • To understand the ne
Slide 14: Nexalin Growth Strategy
Nexalin Growth Strategy Virtual Clinic US Expanding Department Indications Of Defense Global Expansion 14
Slide 15: Virtual Clinic
Virtual Clinic Nexalin Technology: Nexalin promotes and manages the physician/patient relationship in on-line portal Patients: Physicians: Receive evaluation and Physicians prescribe, treatment in privacy of home. monitor and evaluate Treatment is monitored by the treatment compliance and physician
Slide 16: Expanding Indications
Expanding Indications 2022 2031-32 • Anxiety and Depression1 $11.5B $16B • Insomnia2 $3.8B $6.4B • Alzheimer’s and Dementia3 $5.1B $9.7 • Substance Use Disorder4 (SUD) $35.1B $60.1B • Opiate Addiction5 $3.3B $6.1B • Concussion / TBI / PTSD6 $3.3B $7.2B • Chronic Pain7 $69.1 $140B 1. Future Market In
Slide 17: US Department of Defense Partnership
US Department of Defense Partnership • Goals 1. Develop multisite veterans’ study for TBI/PTSD 2. To become a primary contractor 2-stage distribution • Veterans Hospital System (VA) • Active duty / Combat Theatre • Actions taken • Nexalin America division created to deal with US Gov’t (Dept of Defen
Slide 18: Global Expansion
Global Expansion • Joint Venture (JV) formed in Hong Kong to advance the Asia Pacific distribution • Nexalin ADI (Gen-2) approved by China NMPA in 2021 • JV has funded, conducted and published 6 clinicals studies to date • Research performed in leading global psychiatric centers in Asia (funded by J
Slide 19: Revenue Creation | Gen-2 & Gen-3
Revenue Creation | Gen-2 & Gen-3 • Chinese distributor is currently selling Gen-2 ADI Nexalin devices in China • The Company will sell the Gen-2 and Gen-3 ADI Nexalin device to physicians (providers) in the USA • Recurring Revenue | Nexalin Gen-2 ADI device requires single use disposable electrode •
Slide 20: Financial Snapshot as of September 30, 2024
Financial Snapshot as of September 30, 2024 Cash and Short-Term Investments $4.6M Debt $0 Common Shares Outstanding 12.9M Warrants Outstanding (avg $4.15) 2.7M Fully Diluted Shares Including Options 18.4M Management/Director Ownership 24% 20
Slide 21: Executive Management Team
Executive Management Team Mark White --- David Owens M.D. --- Carolyn Shelton ---Sr VP - Marilyn Elson --- Quality, Regulatory, Clinical President and Chief Executive Controller Chief Medical Officer Officer Dr. Owens brings extensive Mrs. Shelton is a seasoned medical Ms. Elson has been a Certified
Slide 22: Advisory Board
Advisory Board John Patrick Claude – Engineering and Product Development (Co-Founder / waveform designer) Mr. John Claude, in conjunction with Dr. Yakov Katsnelson, designed and developed the original tACS waveform that is marketed as Nexalin Technology. John now leads all engineering, research and
Slide 23: Thank You
Thank You
Nexalin Technology — Investor Presentation (December 2024) on 6ix